Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
insulin resistance/obezite
Bağlantı panoya kaydedilir
Sayfa 1 itibaren 467 Sonuçlar
Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010.
FIELD OF THE
Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
Composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008206, filed Nov. 19, 2010, which claims priority from Korea Patent Application 10-2010-0041249, filed May 3, 2010.
BACKGROUND OF THE
Compositions for treating obesity and insulin resistance disorders
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
Compositions for treating obesity and insulin resistance disorders
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
Compositions for treating obesity and insulin resistance disorders
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
Obesity is a chronic condition that is characterized by a body mass index (BMI) over 25. Both congenital and environmental factors, such as exercise and eating habits, contribute to the disease. For instance, the hormone leptin has been shown to be involved in fat accumulation and
Method for treatment of insulin resistance in obesity and diabetes
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention relates to a non-human animal model for obesity and uses of such an animal for studying and developing methods for identifying compounds for use in the regulation of insulin resistance in obesity and type II diabetes, as well as a method of treating
Regulators of PPAR.delta. (.beta.) and their use in the treatment of obesity and insulin resistance
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention relates to a method for treating obesity, insulin resistance and dyslipidemia in mammals including humans through inhibition of PPAR.delta.(.beta.). This invention also relates to methods of screening for chemical entities that act to regulate
Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-.alpha. function
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Obesity and diabetes are among the most common human health problems in industrialized societies. Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals
Treatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha function
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Obesity and diabetes are among the most common human health problems in industrialized societies. Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals
CD36 inhibition to control obesity and insulin sensitivity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
CD36 is a multifunctional receptor that is expressed in various types of cells and tissues including brain microglia and astrocytes as well as monocytes/macrophages and adipocytes. CD36 recognizes many ligands including oxidized or modified low density lipoprotein (oxLDL, mLDL),
RBP4 in insulin sensitivity/resistance, diabetes, and obesity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
RBP4 in insulin sensitivity/resistance, diabetes, and obesity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
RBP4 in insulin sensitivity/resistance, diabetes, and obesity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Insulin resistance in the peripheral tissues such as muscle and fat is associated with increased secretion of insulin by pancreatic .beta.-cells. The secreted insulin promotes glucose utilization and inhibits production of glucose by the liver. However, the pancreatic
Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
The present invention relates to the use of ketoconazole or molecules resembling ketoconazole but with some side-chains, not affecting the biological activity compared to ketoconazole, changed for manufacturing drugs for treatment of diabetes mellitus type II.
The drug ketoconazole (e.g., under the
Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı
- 55 dilde çalışır
- Bilim destekli bitkisel kürler
- Görüntüye göre bitki tanıma
- Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
- Aramanızla ilgili bilimsel yayınları okuyun
- Şifalı bitkileri etkilerine göre arayın
- İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın
Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır
